Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00088010 · ClinicalTrials.gov registry record · Phase 3
Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 9,369
- Enrollment target
NCT00088010 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 9,369 participants.
The verdict
NCT00088010, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 9,369 participants
- Enrollment target
Study Summary
The purpose of this trial is to study: * Effects of arzoxifene on bone fractures and bone mass. * Effects of arzoxifene on getting breast cancer. * Effects of arzoxifene on certain types of cardiovascular events, such as heart attack and stroke. * Effects of arzoxifene that changes the amount of certain substances in the blood that are related to osteoporosis and cardiovascular health. * Effects of arzoxifene on the uterus. * The safety of arzoxifene and any side effects.
Interventions
- DRUG Placebo
- DRUG Arzoxifene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9,369 participants |
| Start Date | 2004-06 |
| Est. Completion | 2009-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00088010
The ClinicalTrials.gov registry entry for NCT00088010 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 9,369 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00088010 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00088010 about?
NCT00088010 is a clinical study titled "Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer". The purpose of this trial is to study: * Effects of arzoxifene on bone fractures and bone mass. * Effects of arzoxifene on getting breast cancer. * Effects of arzoxifene on certain types of cardiovascular events, such as heart attack and stroke. * Effects of arzoxifene that changes the amount of ce...
What is the current status of trial NCT00088010?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 9,369 participants. The study started on 2004-06. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00088010?
The interventions under investigation include: Placebo (DRUG), Arzoxifene (DRUG).
Who is sponsoring clinical trial NCT00088010?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.